Decoding Tumor States Using Tissue Proteomics and Spatial Biology

November 25, 2026

7 AM PST | 10 AM EST | 3PM GMT | 4 PM CET
Biognosys Group hosted live-webinar via Zoom

Register now

Decoding Tumor States Using Clinical Proteomics and Spatial Biology on Patient-Derived Tissue Samples

Recent advances in tissue proteomics are transforming how cancers are classified, characterized, and ultimately treated. In this webinar, leading clinical researchers will showcase how large-scale proteomic and spatial profiling approaches dissect clinically relevant tumor subtypes, reveal mechanisms of therapy resistance, and open new opportunities for precision oncology.

Dr. Hanibal Bohnenberger will present findings from the proteomic analysis of 1,000 colorectal cancer samples, revealing six distinct functional tumor subgroups with unique clinical outcomes and therapeutic vulnerabilities. Dr. Juan Francisco Grau Béjar will discuss how extracellular matrix remodeling drives resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer, highlighting the power of multiproteomic and spatial imaging approaches to identify predictive biomarkers and guide future treatment strategies.

Attendees will learn how discovery proteomics supports clinical decision-making, complements histopathology workflows for enhanced tumor classification, and how Biognosys CRO solutions can enable comprehensive tissue, whole-slide, and laser capture microdissection (LCM)-based proteome profiling.

Agenda

Wednesday, November 25, 2026

Welcome

Christopher Below: Introduction & Biognosys Capabilities Welcome

Talk 1

Hanibal Bohnenberger: Proteomic Subtyping of 1,000 Colorectal Cancers: From Tissue to Tumor State Talk

Talk 2

Juan Francisco Grau-Bejar: Extracellular Matrix Collagen Remodeling Predicts Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer Talk

Closing

Live Q & A Session Session

Webinar

Welcome

Introduction and Biognosys Capabilities

Christopher BelowPrincipal Scientist R&D and Product Owner Discovery Proteomics

Proteomic Subtyping of 1,000 Colorectal Cancers: From Tissue to Tumor State

Deep proteomics of 1,000 treatment-naïve colorectal cancers reveals six functional subgroups, including a split of the chromosomally unstable majority and a rare, previously unrecognized subgroup with adverse outcome. These subgroups differ in clinical course and predicted drug sensitivity and cannot be captured by single markers. Together with 2,500 annotated H&E whole-slide images, the cohort is released as an open resource for functional cancer stratification and computational pathology.

Hanibal BohnenbergerSenior Physician, University Medicine Göttingen, Department of Pathology

Extracellular Matrix Collagen Remodeling Predicts Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer

While immunotherapy has transformed treatment for mismatch repair–deficient endometrial cancer, a significant proportion of patients fail to achieve durable clinical benefit. To understand the mechanisms driving this resistance, our multiproteomic and spatial imaging analyses revealed that extracellular matrix remodeling blocks CD8⁺ T-cell infiltration and drives immunotherapy failure. Ultimately, integrating these structural collagen metrics with immune parameters establishes a promising predictive framework to guide future clinical decision-making and optimize stromal-targeted therapies.

Juan Francisco Grau-BejarMedical Oncologist, PhD Researcher, IGR, Gustave Roussy Institute

Newsletter

Don’t miss out on the latest from Biognosys Group – sign up to receive the latest news, innovations, and expert insights straight to your inbox.

Subscribe for Updates

Subscribe to Our Newsletter